SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structure Therapeutics may offer and sell to certain investors that so choose pre-funded warrants to purchase ordinary shares, represented by ADSs, in lieu of ADSs, in the underwritten public offering. The purchase price of each pre-funded warrant will equal the price per ADS at which the ADSs are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. In addition, Structure Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 ADSs at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. A copy of the registration statement can be accessed through the SEC’s website at www.sec.gov. These securities may not …
Full story available on Benzinga.com
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structure Therapeutics may offer and sell to certain investors that so choose pre-funded warrants to purchase ordinary shares, represented by ADSs, in lieu of ADSs, in the underwritten public offering. The purchase price of each pre-funded warrant will equal the price per ADS at which the ADSs are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. In addition, Structure Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 ADSs at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. A copy of the registration statement can be accessed through the SEC’s website at www.sec.gov. These securities may not …
Full story available on Benzinga.com
SAN FRANCISCO, June 03, 2024 (GLOBE NEWSWIRE) — Structure Therapeutics Inc. (NASDAQ:GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 8,000,000 American depositary shares (ADSs), each representing three ordinary shares. Structure Therapeutics may offer and sell to certain investors that so choose pre-funded warrants to purchase ordinary shares, represented by ADSs, in lieu of ADSs, in the underwritten public offering. The purchase price of each pre-funded warrant will equal the price per ADS at which the ADSs are being sold to the public in this offering, minus $0.0001, which will be the per share exercise price of each pre-funded warrant. In addition, Structure Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional 1,200,000 ADSs at the public offering price, less the underwriting discounts and commissions. The public offering price has not yet been determined. The proposed offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Goldman Sachs & Co. LLC, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities and BMO Capital Markets are acting as joint book-running managers for the proposed offering.
A registration statement relating to these securities has been filed with the SEC but has not yet become effective. A copy of the registration statement can be accessed through the SEC’s website at www.sec.gov. These securities may not …Full story available on Benzinga.com Read MoreGPCR, News, IPOs, Press Releases IPOs
